Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.36 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.34 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19405788 | 0.89 | TYR (0.47) | TYRKDM4EALDH1A1ADORA2AHSD17B3 | |
| SCHEMBL9950301 | 0.83 | KDM4E (0.40) | KDM4EALDH1A1POLBMAPTHSD17B3 | |
| SCHEMBL6985244 | 0.76 | KMT2A (0.43) | TYRKDM4EALDH1A1POLBMAPT | |
| SCHEMBL3161296 | 0.76 | L3MBTL1 (0.45) | KDM4EALDH1A1POLBMAPT | |
| SCHEMBL14507697 | 0.74 | TLR8 (0.45) | KDM4EALDH1A1POLBMAPTADORA2B | |
| SCHEMBL13239668 | 0.73 | LMNA (0.41) | TYRKDM4EALDH1A1POLBMAPT | |
| SCHEMBL13384524 | 0.73 | MAPT (0.37) | TYRKDM4EALDH1A1POLBMAPT | |
| SCHEMBL21395223 | 0.72 | LMNA (0.59) | KDM4EALDH1A1MAPTADORA2BADORA2A | |
| SCHEMBL7247913 | 0.72 | — | — | |
| SCHEMBL8229121 | 0.71 | TYR (0.43) | TYRKDM4EALDH1A1POLBHSD17B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107207444-B | Bicyclic compounds | 武田药品工业株式会社 | 2020-07-24 | — | — | CN | disclosed |
| EP-3225618-B1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-05-06 | — | — | EP | disclosed |
| US-10301292-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-28 | — | — | US | disclosed |
| US-20180002322-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-01-04 | — | — | US | disclosed |
| EP-3225618-A1 | BICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002322-A1 | BICYCLIC COMPOUND | ACACA, ACACB, ACAT1 | TYR 2980/4885KDM4E 1753/4885ALDH1A1 355/4885 |
| US-10301292-B2 | Bicyclic compound | ACACA, ACACB, ACAT1 | TYR 2980/4885KDM4E 1753/4885ALDH1A1 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.